Begin main content

Apomorphine

Last Updated: April 18, 2018
Result type: Reports
Project Number: SR0527-000
Product Line: Common Drug Review

Generic Name: apomorphine hydrochloride

Brand Name: Movapo

Manufacturer: Paladin Labs Inc.

Indications: Parkinson's disease

Submission Type: New

Project Status: Complete

Biosimilar: No

Date Recommendation Issued: January 23, 2018

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

Key Milestones2

Call for patient input postedJune 07, 2017
Patient group input closedJuly 27, 2017
Clarification:

- Patient input submission received

Patient input summary sent for review to patient input groupsAugust 08, 2017
Patient group comments on input summary closedAugust 14, 2017
Clarification:

- Patient input summary feedback received

Submission receivedJuly 06, 2017
Submission accepted for reviewJuly 20, 2017
Review initiatedJuly 21, 2017
Draft CDR review report(s) sent to applicantOctober 25, 2017
Comments from applicant on draft CDR review report(s) receivedNovember 03, 2017
Redaction requests from applicant on draft CDR review report(s) receivedNovember 10, 2017
CDR review team's comments on draft CDR review report(s) sent to applicantDecember 01, 2017
Canadian Drug Expert Committee (CDEC) meetingDecember 13, 2017
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plansJanuary 02, 2018
Embargo period ended and validation of redacted CDR review report(s) receivedJanuary 16, 2018
CDEC Final Recommendation issued to applicant and drug plansJanuary 23, 2018
CDEC Final Recommendation postedJanuary 25, 2018
Final CDR review report(s) and patient input postedFebruary 06, 2018

Tags

apomorphine, parkinson disease, parkinson, Movapo; apomorphine; apokyn; ApoGO; Uprima; Ixense; Parkinson disease; Parkinsonism; Parkinson's